Eradication of CD19+ leukemia by targeted calicheamicin θ.
about
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I.Novel insights on the DNA interaction of calicheamicin γ1I
P2860
Eradication of CD19+ leukemia by targeted calicheamicin θ.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@en
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@nl
type
label
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@en
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@nl
prefLabel
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@en
Eradication of CD19+ leukemia by targeted calicheamicin θ.
@nl
P2093
P50
P356
P1476
Eradication of CD19+ leukemia by targeted calicheamicin θ
@en
P2093
Aram Prokop
Gerhard Gaedicke
Nicole Huebener
Wolfgang Wrasidlo
P304
P356
10.1021/BC900128H
P577
2009-07-02T00:00:00Z